Form 4: Apogee Therapeutics CEO Exercises Stock Options

Apogee Therapeutics CEO Michael Henderson exercised 3,000 stock options at a price of $22.86 per share.

Summary

• Michael Henderson, CEO of Apogee Therapeutics, exercised 3,000 stock options on April 16, 2026.
• The exercise price for these options was $22.86 per share.
• Following this transaction, the CEO holds 1,135,987 shares of common stock directly.
• The remaining balance of exercisable derivative securities for the CEO is 387,012 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative exercise of equity compensation rather than a market-moving strategic decision.

Positives

• The CEO continues to maintain a significant equity stake in the company, totaling 1,135,987 shares.
• The transaction reflects the utilization of standard equity compensation plans.

Negatives

• None identified.

Risks

• The value of the acquired shares is subject to market volatility and the future performance of Apogee Therapeutics.

Future Outlook

The filing does not provide forward-looking guidance regarding company operations or financial performance.

Industry Context

StockSavvy.ai notes that routine option exercises by executives are standard corporate governance events and generally do not signal a change in strategic direction or outlook for biotechnology firms.

Comparison to Industry Standards

• The exercise of stock options by executive leadership is a common practice in the biotechnology sector as part of standard compensation packages.
• The level of beneficial ownership held by the CEO remains consistent with industry norms for founder-led or early-stage biotech companies.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine exercise of existing equity compensation.

Next Steps

• Continued monitoring of future SEC filings for further changes in insider holdings.

Key Dates

Keywords

Apogee Therapeutics, APGE, Insider Trading, Stock Options, CEO, Form 4